cancer

(redirected from fallopian tube cancer)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
  • noun

Synonyms for cancer

Synonyms for cancer

any malignant growth or tumor caused by abnormal and uncontrolled cell division

(astrology) a person who is born while the sun is in Cancer

a small zodiacal constellation in the northern hemisphere

Related Words

the fourth sign of the zodiac

References in periodicals archive ?
Noting that mutations of BRCA1 or BRCA2 account for 5%-10% of cases of ovarian cancer, she added that "potentially, fallopian tube cancer has an even higher rate of association.
The Canadian investigators also found that 5 of 18 women, or 28%, whose fallopian tube cancer was diagnosed by age 55 were BRCAI or BRCA2 mutation positive.
Fallopian Tube Cancer Therapeutics under Development by Companies
Fallopian Tube Cancer Therapeutics under Investigation by Universities/Institutes
Fallopian Tube Cancer Therapeutics - Products under Development by Companies
The patient with fallopian tube cancer had undergone LAVH and bilateral salpingo-oophorectomy to evaluate an adnexal mass, which ruptured during surgery.
A snapshot of the global therapeutic scenario for Fallopian Tube Cancer.
A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of the Fallopian Tube Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
TRINOVA-2 is evaluating whether trebananib plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival in recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer.
The clinical trial is being carried out at the Ohio State University Comprehensive Cancer Center and is expected to enroll up to 70 patients with metastatic ovarian, peritoneal, or fallopian tube cancers.
NCI Phase I/II systemic and intraperitoneal administration clinical trial for patients with metastatic ovarian, peritoneal and fallopian tube cancers, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements.
Food and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus.
The trial, which is being carried out at The Ohio State University Comprehensive Cancer Center, is expected to enroll up to 70 patients with metastatic ovarian, peritoneal or fallopian tube cancers.
NCI Phase I/II systemic and intraperitoneal administration clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements.